Sunday, April 13, 2008

Premarket Roundup: Genentech Cancer Drug Avastin's Sales Disappoint, Ross Stores Upgraded

Among the premarket stories for Friday, April 11, from AP Financial News:

NEW YORK (AP) -- Analysts are disappointed with sales of Genentech's cancer drug Avastin, as revenue rose only modestly after the drug was approved to treat breast cancer.

NEW YORK (AP) -- A JPMorgan analyst upgraded shares of Ross Stores Inc., saying the discount clothing retailer's stores are beating sales expectations and its low inventories are keeping down costs.

NEW YORK (AP) -- A softening U.S. economy is throttling Harley-Davidson's sales, according to one analyst.

No comments: